Drug Profile
Perhexiline - Heart Metabolics
Alternative Names: Perhexiline maleate - Heart MetabolicsLatest Information Update: 17 Sep 2021
Price :
$50
*
At a glance
- Originator HMBL Limited
- Developer Heart Metabolics Limited
- Class Antihypertensives; Cyclohexanes; Ischaemic heart disorder therapies; Piperidines; Small molecules
- Mechanism of Action Calcium channel antagonists; Carnitine O-palmitoyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hypertrophic cardiomyopathy
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for phase-I development in Hypertrophic-cardiomyopathy(In volunteers) in Australia (PO, Tablet)
- 26 Aug 2017 Efficacy and pharmacodynamics data from a phase I trial in healthy volunteers presented at the Annual Congress of the European Society of Cardiology (ESC-Card-2017)
- 02 Aug 2017 Heart Metabolics Limited terminates a phase II trial due to lack of efficacy in Hypertrophic cardiomyopathy in USA (PO) (NCT02862600)